Bio-Rad Laboratories to acquire Curiosity Diagnostics from Scope Fluidics for $170m.

Bio-Rad Laboratories, a firm that develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets, agreed to acquire Curiosity Diagnostics, a medtech company specialized in systems for molecular diagnostics, from Scope Fluidics, a diagnostic and med tech solutions solutions, for $170m. "Our passion at Scope Fluidics is developing innovative technologies addressing the greatest challenges in global health. The dedicated, entrepreneurial team of highly skilled, specialized personnel of Curiosity Diagnostics is looking forward to further developing the PCR|ONE technology under Bio-Rad’s leadership while we at Scope Fluidics continue to pursue new and current projects in disruptive medical diagnostics," Piotr Garstecki, Scope Fluidics President and Co-Founder.